Last reviewed · How we verify
AGN211745
At a glance
| Generic name | AGN211745 |
|---|---|
| Also known as | Sirna-027 |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration (PHASE2)
- A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN211745 CI brief — competitive landscape report
- AGN211745 updates RSS · CI watch RSS
- Allergan portfolio CI